Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, … Read more
Mineralys Therapeutics, Inc. Common Stock (MLYS) - Total Liabilities
Latest total liabilities as of September 2025: $23.52 Million USD
Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) has total liabilities worth $23.52 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mineralys Therapeutics, Inc. Common Stock - Total Liabilities Trend (2020–2024)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mineralys Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Mineralys Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TriCo Bancshares
NASDAQ:TCBK
|
USA | $8.49 Billion |
|
Russel Metals Inc
PINK:RUSMF
|
USA | $1.10 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.05 Billion |
|
Central Retail Corporation Public Company Limited
BK:CRC
|
Thailand | ฿215.20 Billion |
|
Deliveroo Holdings PLC
PINK:DROOF
|
USA | $580.90 Million |
|
Visual China Group Co Ltd
SHE:000681
|
China | CN¥766.48 Million |
|
Innovative Industrial Properties Inc
NYSE:IIPR
|
USA | $474.57 Million |
|
Ube Industries Ltd
PINK:UBEOF
|
USA | $486.36 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Mineralys Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 25.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mineralys Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mineralys Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual total liabilities of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.65 Million | +39.73% |
| 2023-12-31 | $10.48 Million | -93.71% |
| 2022-12-31 | $166.71 Million | +389.61% |
| 2021-12-31 | $34.05 Million | +569.88% |
| 2020-12-31 | $5.08 Million | -- |